ENSC · Ensysce Biosciences, Inc.
$0.42
+0.03 (+7.70%)
At close · Sep 2
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These matters, among others, raise substantial doubt about the Company's ability to continue as a going concern. While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company's ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company's ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$7.45M
Shares
19.46M
ENSC metrics
58 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.39
Market cap
$7.45M
Price action
19 metricsPrice change (1W)
-3.7%
Price change (30D)
+38.6%
Price change (3M)
+48.1%
Price change (6M)
-23.9%
Price change (YTD)
-57.8%
Price change (1Y)
-81.4%
Trailing year
Price change (5Y)
—
52-week high
$2.57
52-week low
$0.25
Change from 52-week high
-84.9%
Change from 52-week low
+54.6%
Annualized volatility
132.7%
Beta
1.3
RSI (14D)
53.4
Price vs SMA 50
+17.6%
Price vs SMA 200
-37.7%
Avg volume (3M)
14.42M
Relative volume
0.0
Average dollar volume
$6.39M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
19.46M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.7×
reciprocal yield 60.4%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-169.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-18
Profitability
9 metricsGross margin
—
Operating margin
-281.3%
Trailing 12 months
Net margin
-280.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$12.66M
Net income (TTM)
−$12.62M
Trailing 12 months
Diluted EPS (TTM)
$-2.52
FCF margin
—
Effective tax rate
11.9%
Growth
11 metricsRevenue growth YoY
-15.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.50M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+491.9%
Year over year · more shares
Revenue CAGR (3Y)
+26.2%
Revenue CAGR (5Y)
+5.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-426.9%
Debt / equity
—
Current ratio
0.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.7
Interest coverage
-791.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$676,704
Latest balance sheet
Cash & equivalents
$676,704
Total assets
$2.96M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$8.86M
Capital expenditures (TTM)
—
R&D (TTM)
$12.39M
SG&A (TTM)
$20.49M
Stock compensation (TTM)
—
R&D / revenue
275.2%
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
18
13F filer change QoQ
+3
Institutional ownership
4.7%
Short interest
3 metricsShort interest
5.9%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
64 / 100
Insider activity
2 metricsNet insider buying (90D)
$198,000
Insider-sentiment score
86 / 100
Risk flags
1 metricsGoing concern
Flagged
Key facts
CIK
1716947
CUSIP
293602504
13F (30d)
17 filings
17 filers
Visit website
Investor relations